Eleven Biotherapeutics (EBIO) Reports Q4 Loss of $0.53/Share

Eleven Biotherapeutics (NASDAQ: EBIO) reported Q4 EPS of ($0.53), versus ($0.49) reported last year. Revenue for the quarter came in at $600 thousand, versus $400 thousand reported last year.

For earnings history and earnings-related data on Eleven Biotherapeutics (EBIO) click here.

You May Also Be Interested In

• Gogoro Inc (GGR) Reports Q2 Loss of $0.24, Offers FY26 Revenue Guidance
• H.B. Fuller board rejects Ancora's $1.1B-$1.2B BAS unit bid
• Howmet Aerospace Inc. (HWM) PT Raised to $328 at Bernstein SocGen Group